We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Tiziana Life Sciences has entered an agreement with FHI Clinical to carry out a Phase II proof-of-concept clinical trial of intranasal Foralumab in severe Covid-19 patients hospitalised with pulmonary inflammation in Brazil.